Downregulation of LINC01140 is associated with adverse features of breast cancer

Li,Deheng; Li,Liangdong; Cao,Yiqun; Chen,Xin

doi:10.3892/ol.2019.11147

Downregulation of LINC01140 is associated with adverse features of breast cancer

Authors:
- Deheng Li
- Liangdong Li
- Yiqun Cao
- Xin Chen
View Affiliations

Affiliations: Department of Neurosurgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: November 25, 2019 https://doi.org/10.3892/ol.2019.11147
Pages: 1157-1164
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is one of the most dangerous malignant diseases among women. A growing amount of evidence has suggested that long non‑coding RNAs participate in the development and progression of BC and may potentially serve as therapeutic targets or prognostic markers for the disease. A previous study demonstrated that long intergenic non‑protein coding RNA 01140 (LINC01140) was prominently correlated with overall survival in patients with gastric cancer. However, the function of LINC01140 in BC has not yet been elucidated. Therefore, the present study aimed to investigate the roles and molecular mechanisms underlying LINC01140 in BC. LINC01140 expression in 1,085 breast cancer patients and 291 healthy subjects was analyzed from the Gene Expression Profiling Interactive Analysis website. The association between LINC01140 expression and T stages, LINC01140‑related biological pathways, and the correlation between LINC01140 expression genes were also analyzed in 825 patients with BC through the cBioPortal database. The present study demonstrated that LINC01140 expression was significantly decreased in the tumor samples compared with normal samples in patients with BC (P<0.05). The present study revealed that LINC01140 expression was significantly decreased in the T4 stage compared with T1, T2 or T3 stage (P<0.01). In addition, high expression levels of LINC01140 predicts longer relapse‑free survival probability in patients with BC. It was also observed that LINC01140 participates in a variety of biological pathways, particularly in the epithelial‑to‑mesenchymal transition. The co‑expression relationship between the LINC01140 and an abundance of genes in samples from the BC study was investigated. These genes, such as chordin like 1 and bone morphogenic protein 6, participate in the development and progression of tumor growth and bone metastasis. Finally, the present study observed the interaction between microRNA (miR)‑200b and miR‑200c with LINC011440. The results from the present study indicated that higher expression of LINC01140 was beneficial for patients with BC. LINC01140 may be a potential biomarker for the prognosis of patients with BC. The role of LINC01140 in BC needs to be further evaluated.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Fan LM, Strasser-Weippl KM, Li JM, St Louis JB, Finkelstein DMP, Yu KM, Chen WM, Shao ZM and Goss PEP: Breast cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Akram M, Iqbal M, Daniyal M and Khan AU: Awareness and current knowledge of breast cancer. Biol Res. 50:332017. View Article : Google Scholar : PubMed/NCBI
4	Hu X, Liu Y, Du Y, Cheng T and Xia W: Long non-coding RNA BLACAT1 promotes breast cancer cell proliferation and metastasis by miR-150-5p/CCR2. Cell Biosci. 9:142019. View Article : Google Scholar : PubMed/NCBI
5	Jiang Y, Du F, Chen F, Qin N, Jiang Z, Zhou J, Jiang T, Pu Z, Cheng Y, Chen J, et al: Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population. Mol Carcinogen. 56:2048–2057. 2017. View Article : Google Scholar
6	Liu Y, Sharma S and Watabe K: Roles of lncRNA in breast cancer. Front Biosci (Schol Ed). 7:94–108. 2015. View Article : Google Scholar : PubMed/NCBI
7	Niknafs YS, Han S, Ma T, Speers C, Zhang C, Wilder-Romans K, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al: The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun. 7:127912016. View Article : Google Scholar : PubMed/NCBI
8	Batista PJ and Chang HY: Long noncoding RNAs: Cellular address codes in development and disease. Cell. 152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
9	Song P, Jiang B, Liu Z, Ding J, Liu S and Guan W: A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. Cancer Med. 6:1154–1164. 2017. View Article : Google Scholar : PubMed/NCBI
10	Li J, Han L, Roebuck P, Diao L, Liu L, Yuan Y, Weinstein JN and Liang H: TANRIC: An interactive open platform to explore the function of lncRNAs in cancer. Cancer Res. 75:3728–3737. 2015. View Article : Google Scholar : PubMed/NCBI
11	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
12	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
13	Nagy Á, Lánczky A, Menyhárt O and Győrffy B: Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 8:92272018. View Article : Google Scholar : PubMed/NCBI
14	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
15	Pathan M, Keerthikumar S, Ang C, Gangoda L, Quek CYJ, Williamson NA, Mouradov D, Sieber OM, Simpson RJ, Salim A, et al: FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 15:2597–2601. 2015. View Article : Google Scholar : PubMed/NCBI
16	Li JH, Liu S, Zhou H, Qu LH and Yang JH: starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
17	Dongre A and Weinberg RA: New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20:69–84. 2019. View Article : Google Scholar : PubMed/NCBI
18	Voutsadakis I: Epithelial-Mesenchymal Transition (EMT) and regulation of EMT factors by steroid nuclear receptors in breast cancer: A review and in silico investigation. J Clin Med. 5(pii): E112016. View Article : Google Scholar : PubMed/NCBI
19	Balemans W and Van Hul W: Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol. 250:231–250. 2002. View Article : Google Scholar : PubMed/NCBI
20	Attisano L and Wrana JL: Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 7:327–339. 1996. View Article : Google Scholar : PubMed/NCBI
21	Cyr-Depauw C, Northey JJ, Tabariès S, Annis MG, Dong Z, Cory S, Hallett M, Rennhack JP, Andrechek ER and Siegel PM: Chordin-like 1 suppresses bone morphogenetic protein 4-induced breast cancer cell migration and invasion. Mol Cell Biol. 36:1509–1525. 2016. View Article : Google Scholar : PubMed/NCBI
22	Pei YF, Zhang YJ, Lei Y, Wu DW, Ma TH and Liu XQ: Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer. Oncotarget. 8:23155–23166. 2017. View Article : Google Scholar : PubMed/NCBI
23	Zhang M, Wang Q, Yuan W, Yang S, Wang X, Yan J, Du J, Yin J, Gao SY, Sun BC and Zhu TH: Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells. J Steroid Biochem Mol Biol. 105:91–97. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE and Robson CN: Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res. 57:4427–4431. 1997.PubMed/NCBI
25	Maki DD and Grossman RI: Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. Am J Neuroradiol. 21:1064–1066. 2000.PubMed/NCBI
26	Mekala JR, Naushad SM, Ponnusamy L, Arivazhagan G, Sakthiprasad V and Pal-Bhadra M: Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. Gene. 641:248–258. 2018. View Article : Google Scholar : PubMed/NCBI
27	Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C and Zhang Q: DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett. 359:198–205. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhang G, Zhang W, Li B, Stringer-Reasor E, Chu C, Sun L, Bae S, Chen D, Wei S, Jiao K, et al: MicroRNA-200c and microRNA-141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res. 19:732017. View Article : Google Scholar : PubMed/NCBI
29	Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI